Dr. Kathleen Michelle Leahy, MD, MPH

Dr. Leahy practices at The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts.

Dr. Leahy's NPI, 1275913014, was assigned on June 7, 2015. Dr. Leahy graduated from Boston University School of Medicine in 2015. Dr. Leahy holds Massachusetts license 264073.

Dr. Leahy's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD, at 148 Chestnut St, Needham, MA 02492.

Dr. Leahy's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts. Dr. Leahy is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Leahy to 4 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leahy practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Leahy's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Leahy is licensed in Massachusetts.

CMS data shows 215 Medicare services from Dr. Leahy across 5 procedure codes in 2024, all of them office visits, for 167 Medicare patients. Medicare paid $15,844 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 167 Medicare patients who saw Dr. Leahy in 2024. The largest group is 75 to 84, with 77 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leahy's median patient age at 66, with 71% women.

In 2024, Dr. Leahy wrote 438 Medicare Part D claims for 126 patients. 79% of them were for generic drugs. CMS names the drug for 322 of them, across 10 drugs with 11 or more claims each, at $233,483 in total drug cost. In 2023, CMS named 534 claims across 13 drugs.

Dr. Leahy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leahy as offering telehealth.

Dmand AI links 13 papers to Dr. Leahy, published from 2011 to 2022. 2011 was the busiest year, with 2. The most frequent topics are Malus, Pheromones and Bone Neoplasms. Dr. Leahy has published most often in Environ Entomol. Dr. Leahy's most frequent co-authors are Gregory D. Longmore, MD, Katherine N. Weilbaecher, MD and Utkarsh Acharya, DO.

CMS Open Payments shows 4 general payments to Dr. Leahy from 2 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Sanofi and Genzyme US Companies paid the most, $199.

Dr. Leahy graduated from Boston University School of Medicine in 2015.